Long non-coding RNAs in recurrent ovarian cancer: Theranostic perspectives

Vipul Bhardwaj, Yan Qin Tan, Ming Ming Wu, Lan Ma, Tao Zhu, Peter E. Lobie, Vijay Pandey

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Nearly 70% of ovarian cancer (OC) patients experience recurrence within the first 2 years after initial treatment. Emerging evidence indicates that long non-coding RNAs (lncRNAs) play a pivotal role in the pathogenesis of OC progression, resistance to therapy and recurrent OC (ROC). Transcriptome profiling studies have reported differential expression patterns of lncRNAs in OC which are related to increased cell invasion, metastasis and drug resistance. In this review, we highlighted the roles of lncRNAs in OC progression and outlined the potential molecular mechanisms by which lncRNAs impact on ROC. Recent advances using lncRNAs as potential biomarkers for screening, detection, prediction, response to therapy and as therapeutic targets are discussed.

Original languageEnglish (US)
Pages (from-to)97-107
Number of pages11
JournalCancer Letters
StatePublished - Apr 1 2021


  • Cancer biomarker
  • Drug resistance
  • LncRNA
  • Metastasis
  • ROC
  • Recurrence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Long non-coding RNAs in recurrent ovarian cancer: Theranostic perspectives'. Together they form a unique fingerprint.

Cite this